Schellenberg Wittmer advised Bioventure Club Deal Nine GmbH & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting obesity and associated metabolic diseases.
The team of Schellenberg Wittmer consisted of Oliver Triebold, Elia Claude Schunck, Laura Roth (all Corporate/M&A), Michael Nordin and Roland Wild (both Tax).
Copy linkLink copied
+41 44 215 9386
+41 44 215 5269
This site is protected by reCAPTCHA and the Google
Terms of Service apply.